Bioresorbable bone adhesives may provide remarkable clinical solutions in areas ranging from fixation and osseointegration of permanent implants to the direct healing and fusion of bones without permanent fixation hardware. Mechanical properties of bone adhesives are critical for their successful application in vivo. Reinforcement of a tetracalcium phosphate–phosphoserine bone adhesive is investigated using three degradable reinforcement strategies: poly(lactic‐co‐glycolic) (PLGA) fibers, PLGA sutures, and chitosan lactate. All three approaches lead to higher compressive strengths of the material and better fatigue performance. Reinforcement with PLGA fibers and chitosan lactate results in a 100% probability of survival of samples at 20 MPa maximum compressive stress level, which is almost ten times higher compared to compressive loads observed in the intervertebral discs of the spine in vivo. High adhesive shear strength of 5.1 MPa is achieved for fiber‐reinforced bone adhesive by tuning the surface architecture of titanium samples. Finally, biological and biomechanical performance of the fiber‐reinforced adhesive is evaluated in a rabbit distal femur osteotomy model, showing the potential of the bone adhesive for clinical use.

中文翻译：

---

生物启发的矿物-有机生物可吸收骨粘合剂的增强和疲劳

可生物吸收的骨粘合剂可以在从永久性植入物的固定和骨整合到没有永久性固定硬件的骨骼的直接愈合和融合等领域提供出色的临床解决方案。骨粘合剂的机械性能对其在体内的成功应用至关重要。一磷酸四磷酸丝氨酸骨粘合剂加固使用三个降解加强策略研究：聚（乳酸-共-乙醇酸（PLGA）纤维，PLGA缝线和壳聚糖乳酸。所有这三种方法都会导致材料具有更高的抗压强度和更好的疲劳性能。PLGA纤维和壳聚糖乳酸的增强导致样品在20 MPa最大压缩应力水平下存活的可能性为100％，这比在体内脊椎椎间盘中观察到的压缩载荷几乎高十倍。通过调整钛样品的表面结构，纤维增强骨粘合剂的粘合剪切强度达到5.1 MPa。最后，在兔股骨远端截骨模型中评估了纤维增强粘合剂的生物学和生物力学性能，表明了该骨粘合剂在临床上的潜力。